Telomir Pharmaceuticals EBIT

Telomir Pharmaceuticals (TELO) currently reports a EBIT of $-6M as of June 2026. That compares with $-18M in the prior-year period — up 66.5% year over year. That is above the sector sector average of $-6.4M. Use the charts on this page to explore Telomir Pharmaceuticals's EBIT history and peer comparisons.

Telomir Pharmaceuticals's EBIT increased from $-18M to $-6M — a 66.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Telomir Pharmaceuticals's EBIT of $-6M is higher than the its sector sector average of $-6.4M. That is roughly 5.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Telomir Pharmaceuticals reported $-6M in EBIT as of June 2026. That compares with $-18M in the prior-year period — up 66.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-6M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Telomir Pharmaceuticals, and consider following TELO for alerts when major investors trade the stock.